However, programmed orthotopic administration of the MCT inhibitor CHC by osmotic pumps into gliomas implanted into rats has been shown to substantially decrease invasion and to lead to necrosis within the tumor bed [144]. The gene discussed is SLC16A1; the disease is neoplasm.